Meet the Neurvati and GRIN Therapeutics, Inc. team at the International League Against Epilepsy’s 15th European Epilepsy Congress as we present new data from our Phase 1b Honeycomb clinical trial evaluating our investigational drug as a potential treatment for children with GRIN-related disorder. #EEC2024
At the International League Against Epilepsy’s 15th European Epilepsy Congress in Rome, Italy, from September 7 to 11, we will present new data from the Honeycomb Study, our Phase 1b open-label clinical trial evaluating our investigational drug for the treatment of GRIN-related disorder. Professor Renzo Guerrini, M.D., will deliver a poster presentation on the safety, tolerability, pharmacokinetics, and effect on seizure frequency and behavior of individually titrated doses of our investigational drug in children with GRIN-related disorder. See our press release for more information: https://lnkd.in/epZNea8k #EEC2024